Importance Myasthenia gravis (MG), an autoimmune disorder of neuromuscular
transmission, is treated by an array of immunotherapeutics, many of which are nonspecific.
Even with current therapies, a subset of patients has medically refractory MG. The benefits of
B-cell–targeted therapy with rituximab have been observed in MG; however, the duration of
these benefits after treatment is unclear. Objective To evaluate the durability of response to
rituximab in the treatment of acetylcholine receptor autoantibody–positive (AChR+) …